|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
6/21/2006 12:57:25 PM
RALEIGH, N.C.--(BUSINESS WIRE)--June 21, 2006--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP - News) today announced that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) goal date of August 2, 2006 for MoviPrep® (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution). As previously announced, the FDA issued an approvable letter for MoviPrep on April 10, 2006 indicating that approval is contingent upon the resolution of certain manufacturing issues. Salix and Norgine, the product's innovator, collaborated to resolve these issues and filed a resubmission to the new drug application for MoviPrep on June 2, 2006. The FDA has acknowledged the receipt of the submission and considers it to be a complete, Class I response to the April 10, 2006 action letter. The FDA has established August 2, 2006 as the user fee goal date.
|
|
|
|
|
|
|
|
|
|
|